Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial

被引：0
|
作者：
Goadsby, P. J. [1 ]
Reuter, U. [2 ]
Bonner, J. [3 ]
Broessner, G. [4 ]
Hallstrom, Y. [5 ]
Zhang, F. [6 ]
Sapra, S. [6 ]
Picard, H. [6 ]
Mikol, D. D. [6 ]
Lenz, R. A. [6 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Charite, Berlin, Brandenburg, Germany
[3] Mercy Res, St Louis, MO USA
[4] Med Univ Innsbruck, Innsbruck, Austria
[5] Stockholm Neuro Ctr, Stockholms Lan, Sweden
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
HEADACHE | 2017年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IOR04
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [1] Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: primary results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 117 - 117
  • [2] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, Peter
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E104 - E104
  • [3] Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [4] PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL
    Goadsby, Peter J.
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [5] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Tepper, S. J.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. L.
    Silberstein, S. D.
    Winner, P.
    Leonardi, D. K.
    Mikol, D. D.
    HEADACHE, 2017, 57 : 130 - 130
  • [6] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
    Tepper, S.
    Widnell, K.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. Lewis
    Silberstein, S.
    Winner, P.
    Leonardi, D.
    Mikol, D.
    CEPHALALGIA, 2016, 36 : 44 - 45
  • [7] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Paler, Kerry
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E98 - E98
  • [8] A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: Primary results of the ARISE trial
    Ashina, M.
    Dodick, D.
    Kudrow, D.
    Lanteri-Minet, M.
    Osipova, V.
    Palmer, K.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 470 - 470
  • [9] Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine
    Lenz, R.
    Silberstein, S.
    Dodick, D.
    Reuter, U.
    Ashina, M.
    Saper, J.
    Cady, R.
    Chon, Y.
    Dietrich, J.
    Sun, H.
    CEPHALALGIA, 2015, 35 : 5 - 5
  • [10] Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
    Tepper, Stewart
    Widnell, Katherine
    Dolezil, David
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Silberstein, Stephen
    Winner, Paul
    Leonardi, Dean
    Mikol, Dan
    NEUROLOGY, 2017, 88
12345